MEDP Medpace (MEDP) Insider Trading, Ownership & Congress Trades
Pharma & Biotech · Services-commercial physical & biological research · CIK 0001668397
Congress · 1Form 144 · 8
Insider buyers, 180 days
0
Funds added, last quarter
284
13F, latest reported quarter
Conversions, 180 days
17
Codes C/M, not in net · $6.1M priced
What the filings say about MEDP
Insiders, 180 days
-$215.8M net sold
8 sellers · 0% of sales under a 10b5-1 plan
Congress, 1 year
1 bought · 2 sold
Latest: purchase, 2026-05-15
Planned sales (Form 144), 90 days
$26.7M
8 notices
Medpace insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, Medpace Holdings, Inc. insiders sold a net $215.8M of stock across 346 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- 170 earlier Form 4 trades (code P or S) here by this insider (17 buys, 153 sales), the last on Sep 29, 2026.
- +32.9% median (+32.3% mean) 90-day return after 17 previous buys.
- The trade is 6.5% of the 338,225 shares held after it.
- No other insider sold within 30 days.
- 284 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: President & CEO Troendle August J. sold about $13.7M of MEDP on Sep 30, 2026; 284 funds added in the latest 13F quarter.Context
- 169 earlier Form 4 trades (code P or S) here by this insider (17 buys, 152 sales), the last on Sep 28, 2026.
- +32.9% median (+32.3% mean) 90-day return after 17 previous buys.
- The trade is 7.4% of the 360,191 shares held after it.
- No other insider sold within 30 days.
- 284 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: President & CEO Troendle August J. sold about $16.6M of MEDP on Sep 29, 2026; 284 funds added in the latest 13F quarter.Context
- 168 earlier Form 4 trades (code P or S) here by this insider (17 buys, 151 sales), the last on Sep 25, 2026.
- +32.9% median (+32.3% mean) 90-day return after 17 previous buys.
- The trade is 0.6% of the 386,892 shares held after it.
- No other insider sold within 30 days.
- 284 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: President & CEO Troendle August J. sold about $1.5M of MEDP on Sep 28, 2026; 284 funds added in the latest 13F quarter.Context
- 167 earlier Form 4 trades (code P or S) here by this insider (17 buys, 150 sales), the last on Sep 24, 2026.
- +32.9% median (+32.3% mean) 90-day return after 17 previous buys.
- The trade is 0.0% of the 389,302 shares held after it.
- 1 other insider sold within 30 days.
- 284 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: President & CEO Troendle August J. sold about $95.6K of MEDP on Sep 25, 2026; 1 other insider sold within 30 days and 284 funds added in the latest 13F quarter.Context
- 166 earlier Form 4 trades (code P or S) here by this insider (17 buys, 149 sales), the last on Sep 23, 2026.
- +32.9% median (+32.3% mean) 90-day return after 17 previous buys.
- The trade is 7.1% of the 389,456 shares held after it.
- 1 other insider sold within 30 days.
- 284 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: President & CEO Troendle August J. sold about $17.3M of MEDP on Sep 24, 2026; 1 other insider sold within 30 days and 284 funds added in the latest 13F quarter.346 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net -$215.8M over 180 days
-$199.6M over 90 days · -$190.9M of it by a 10%+ holder
below 98% of Pharma & Biotech
Congress
1 member bought in the last year
the lowest in Pharma & Biotech
Funds
284 funds bought in last quarter
more than 95% of Pharma & Biotech
Revenue
+20.0% year over year
more than 66% of Pharma & Biotech
Margin
17.8% net margin
more than 87% of Pharma & Biotech
Buybacks
$294.8M repurchased, FY to 2026-09-30
more than 80% of Pharma & Biotech
Short interest
7.1% of the float short (float per yahoo 2026-10-27) · 6.6 days to cover · settled 2026-10-15
more than 56% of Pharma & Biotech
What changed in the last 30 days
Oct 27Officer BURWIG SUSAN E filed to sell $2.7M by Oct 27 (Form 144)
Why it matters
A Form 144 is a notice of intent to sell; the sale may not happen, and it says nothing about the price.
Oct 26Officer BURWIG SUSAN E filed to sell $10.9M by Oct 26 (Form 144)
Why it matters
A Form 144 is a notice of intent to sell; the sale may not happen, and it says nothing about the price.
Oct 1President & CEO Troendle August J. sold $31.9M (4 trades, Sep 25 to Sep 30)
Watch MEDP
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+13.4%12M
Insider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns MEDP: institutional holders (13F)
13F holdings, latest reported quarter
2,498,248 sh
$1.3B
1,278,935 sh
$677.3M
1,133,357 sh
$600.2M
1,026,820 sh
$543.8M
710,895 sh
$376.5M
Congress trades in MEDP
STOCK Act disclosures, US House only, filed up to 45 days after the trade
Bought 2026-05-15 · disclosed 13 days later
$1,001 - $15,000
Bought 2026-02-26 · disclosed 8 days later
$1,001 - $15,000
Bought 2026-01-29 · disclosed 4 days later
$1,001 - $15,000
Sold 2026-01-16 · disclosed 17 days later
$1,001 - $15,000
Sold 2026-01-15 · disclosed 29 days later
$15,001 - $50,000
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
MEDP planned insider sales (Form 144)
Notice of intent to sell, filed before any sale
BURWIG SUSAN E
Filed 2026-10-27
$2.7M
BURWIG SUSAN E
Filed 2026-10-26
$10.9M
Kraft Robert O.
Filed 2026-08-26
$2.4M
Brady Kevin M.
Filed 2026-08-20
$2.1M
Carley Brian T
Filed 2026-08-19
$3.0M
MEDP mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
Vulcan Value Partners Small Cap Fund
$3.7M position · as of 2026-07-31
4.5%
Wasatch Long/Short Alpha Fund
$1.6M position · as of 2026-06-30
4.1%
Madison Mid Cap Fund
$64.1M position · as of 2026-07-31
3.7%
LIVE OAK HEALTH SCIENCES FUND
$2.1M position · as of 2026-07-31
3.7%
StockSnips AI-Powered Sentiment US All Cap ETF
$716.2K position · as of 2026-07-31
3.7%
ERSHARES GLOBAL ENTREPRENEURS
$1.5M position · as of 2026-06-30
3.6%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Executive pay vs shareholder return · August J. Troendle
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$11.4M
$11.7M
$2.2M
+303%
-1%
2024
$8.6M
$17.7M
$4.2M
+139%
-19%
2023
$1.6M
$9.3M
$918.6K
+120%
-18%
2022
$1.9M
$12.9M
$1.0M
+53%
-23%
2021
$5.9M
$7.7M
$2.0M
+56%
-4%
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $215.8M sold by insiders over 180 days, 284 funds added last quarter, 1 House member(s) bought in 12 months, disclosed weeks after the trade, $26.7M in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
MEDP financials
Revenue growth
+20.0%
XBRL, annual
Net margin
17.8%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$2.8B
four quarters, 2025-10-01 to 2026-09-30
Revenue, TTM MEDP
| FY Dec 2025 | $2.5B |
| FY Dec 2024 | $2.1B |
| FY Dec 2023 | $1.9B |
| FY Dec 2022 | $1.5B |
| FY Dec 2021 | $1.1B |
| Sep 2026 | $716.0M |
| Jun 2026 | $707.3M |
| Mar 2026 | $706.6M |
| Dec 2025 | $708.5M |
| Sep 2025 | $659.9M |
| Jun 2025 | $603.3M |
| Mar 2025 | $558.6M |
| Dec 2024 | $536.6M |
At each fiscal year end
Single quarter
Net margin, TTM
+18.2%
net income over revenue, 2025-10-01 to 2026-09-30
Net margin, TTM MEDP
| FY Dec 2025 | +17.8% |
| FY Dec 2024 | +19.2% |
| FY Dec 2023 | +15.0% |
| FY Dec 2022 | +16.8% |
| FY Dec 2021 | +15.9% |
| Sep 2026 | +19.2% |
| Jun 2026 | +17.2% |
| Mar 2026 | +17.5% |
| Dec 2025 | +19.1% |
| Sep 2025 | +16.8% |
| Jun 2025 | +15.0% |
| Mar 2025 | +20.5% |
| Dec 2024 | +21.8% |
At each fiscal year end
Single quarter
Free cash flow, TTM
$667.6M
operating cash flow minus capex, 2025-10-01 to 2026-09-30
Free cash flow, TTM MEDP
| FY Dec 2025 | $681.9M |
| FY Dec 2024 | $572.3M |
| FY Dec 2023 | $396.7M |
| FY Dec 2022 | $351.2M |
| FY Dec 2021 | $235.1M |
| Sep 2026 | $196.4M |
| Jun 2026 | $138.1M |
| Mar 2026 | $145.0M |
| Dec 2025 | $188.1M |
| Sep 2025 | $235.5M |
| Jun 2025 | $142.4M |
| Mar 2025 | $115.8M |
| Dec 2024 | $183.0M |
At each fiscal year end
Single quarter
Debt to equity
0.00x
long-term 2019-12-31 (82 months older than the period end) plus current 2023-12-31 (33 months older than the period end); equity 2026-09-30
Debt to equity MEDP
| FY Dec 2025 | 0.00x |
| FY Dec 2024 | 0.00x |
| FY Dec 2023 | 0.00x |
| FY Dec 2022 | 0.13x |
| FY Dec 2021 | 0.00x |
| Sep 2026 | 0.00x |
| Jun 2026 | 0.00x |
| Mar 2026 | 0.00x |
| Dec 2025 | 0.00x |
| Sep 2025 | 0.00x |
| Jun 2025 | 0.00x |
| Mar 2025 | 0.00x |
| Dec 2024 | 0.00x |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
n/a
no debt to cover
Cash flow to debt MEDP
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | 7.76x |
| FY Dec 2021 | n/a |
| Sep 2026 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
+117.9%
TTM net income over average of 2025-09-30 and 2026-09-30
Return on equity MEDP
| FY Dec 2025 | +70.2% |
| FY Dec 2024 | +58.4% |
| FY Dec 2023 | +59.8% |
| FY Dec 2022 | +36.6% |
| FY Dec 2021 | +20.7% |
| Sep 2026 | +117.9% |
| Jun 2026 | +162.2% |
| Mar 2026 | +77.3% |
| Dec 2025 | +70.2% |
| Sep 2025 | +73.7% |
| Jun 2025 | +89.4% |
| Mar 2025 | +65.8% |
| Dec 2024 | +58.4% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
+25.5%
TTM net income over average of 2025-09-30 and 2026-09-30
Return on assets MEDP
| FY Dec 2025 | +22.1% |
| FY Dec 2024 | +21.5% |
| FY Dec 2023 | +18.8% |
| FY Dec 2022 | +16.3% |
| FY Dec 2021 | +11.9% |
| Sep 2026 | +25.5% |
| Jun 2026 | +27.1% |
| Mar 2026 | +22.9% |
| Dec 2025 | +22.1% |
| Sep 2025 | +22.6% |
| Jun 2025 | +24.0% |
| Mar 2025 | +22.5% |
| Dec 2024 | +21.5% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
invested capital is zero or negative
Return on invested capital MEDP
| FY Dec 2025 | +753.3% |
| FY Dec 2024 | +161.7% |
| FY Dec 2023 | +84.5% |
| FY Dec 2022 | +50.9% |
| FY Dec 2021 | +35.1% |
| Sep 2026 | n/a |
| Jun 2026 | +1,674% |
| Mar 2026 | +926.8% |
| Dec 2025 | +753.3% |
| Sep 2025 | +363.1% |
| Jun 2025 | +212.9% |
| Mar 2025 | +189.5% |
| Dec 2024 | +161.7% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
+95.2%
operating income (EBIT proxy) over average of 2025-09-30 and 2026-09-30 minus current liabilities
Return on capital employed MEDP
| FY Dec 2025 | +65.7% |
| FY Dec 2024 | +51.7% |
| FY Dec 2023 | +52.6% |
| FY Dec 2022 | +33.7% |
| FY Dec 2021 | +19.3% |
| Sep 2026 | +95.2% |
| Jun 2026 | +119.9% |
| Mar 2026 | +72.2% |
| Dec 2025 | +65.7% |
| Sep 2025 | +67.1% |
| Jun 2025 | +74.7% |
| Mar 2025 | +56.5% |
| Dec 2024 | +51.7% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
37.58x
close 2026-10-26 over four quarters of diluted EPS, 2025-10-01 to 2026-09-30
P/E, trailing MEDP
| FY Dec 2025 | 36.78x |
| FY Dec 2024 | 26.30x |
| FY Dec 2023 | 34.52x |
| FY Dec 2022 | 29.10x |
| FY Dec 2021 | 45.25x |
| Sep 2026 | 34.66x |
| Jun 2026 | 31.10x |
| Mar 2026 | 30.24x |
| Dec 2025 | 36.78x |
| Sep 2025 | 35.96x |
| Jun 2025 | 23.34x |
| Mar 2025 | 23.26x |
| Dec 2024 | 26.30x |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$18.2B
market value at close 2026-10-26 on 2026-10-16 shares, plus long-term 2019-12-31 (82 months older than the period end) plus current 2023-12-31 (33 months older than the period end), minus cash 2026-09-30
Enterprise value MEDP
| FY Dec 2025 | $15.3B |
| FY Dec 2024 | $9.7B |
| FY Dec 2023 | $9.2B |
| FY Dec 2022 | $6.6B |
| FY Dec 2021 | $7.4B |
| Sep 2026 | $16.7B |
| Jun 2026 | $14.6B |
| Mar 2026 | $13.0B |
| Dec 2025 | $15.3B |
| Sep 2025 | $14.2B |
| Jun 2025 | $9.0B |
| Mar 2025 | $8.8B |
| Dec 2024 | $9.7B |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
+3.5%
TTM free cash flow over market value at close 2026-10-26
FCF yield MEDP
| FY Dec 2025 | +4.3% |
| FY Dec 2024 | +5.5% |
| FY Dec 2023 | +4.2% |
| FY Dec 2022 | +5.3% |
| FY Dec 2021 | +3.0% |
| Sep 2026 | +3.8% |
| Jun 2026 | +4.7% |
| Mar 2026 | +5.2% |
| Dec 2025 | +4.3% |
| Sep 2025 | +4.7% |
| Jun 2025 | +6.4% |
| Mar 2025 | +5.8% |
| Dec 2024 | +5.5% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
1.45x
P/E over trailing EPS growth of 26%: four quarters to 2026-09-30 against the four to 2025-09-30
PEG, trailing MEDP
| FY Dec 2025 | 1.76x |
| FY Dec 2024 | 0.62x |
| FY Dec 2023 | 1.59x |
| FY Dec 2022 | 0.56x |
| FY Dec 2021 | 1.77x |
| Sep 2026 | 1.34x |
| Jun 2026 | 1.17x |
| Mar 2026 | 1.42x |
| Dec 2025 | 1.76x |
| Sep 2025 | 1.43x |
| Jun 2025 | 0.88x |
| Mar 2025 | 0.69x |
| Dec 2024 | 0.62x |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $2.5B | $2.1B | $1.9B | $1.5B |
| Operating income | $534.9M | $446.9M | $336.8M | $278.7M |
| Net income | $451.1M | $404.4M | $282.8M | $245.4M |
| EPS (diluted) | 15.28 | 12.63 | 8.88 | 7.28 |
| Operating cash flow | $713.2M | $608.8M | $433.4M | $388.1M |
| Cash | $497.0M | $669.4M | $245.4M | $28.3M |
| Buybacks | $917.4M | $169.9M | $144.0M | $847.8M |
SEC XBRL, fiscal years, as known on 2026-10-28
MEDP Stock Sonar score 6/7 axes
Find similar shapesCompareMEDP ranks highest on financial health (99th percentile) and profitability (97th), and lowest on insider conviction (1st), among Pharma & Biotech peers.
6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
MEDP filings, in plain words
Are Medpace insiders buying or selling MEDP?
In the 180 days to 2026-10-28, Medpace insiders were net sellers, a net $215.8M across purchases and sales reported on Form 4, by 8 sellers.
Have members of Congress traded MEDP?
Yes. In the year to 2026-10-28, 1 House member disclosed buying MEDP and 2 House members disclosed selling it; the latest on record is a purchase by David J. Taylor dated 2026-05-15.
Are there planned insider sales of MEDP?
Yes. 8 Form 144 notices of planned insider sales were filed in the 90 days to 2026-10-28, covering $26.7M of stock; the latest, by BURWIG SUSAN E, was filed 2026-10-27.
Read the full summary
In the 180 days to 2026-10-28, Medpace insiders were net sellers of MEDP, a net $215.8M across purchases and sales reported on Form 4 by 8 sellers. Most of that figure, $190.9M, came from a holder of 10% or more rather than an officer or director. None of the 32 insider sales was flagged as made under a Rule 10b5-1 plan. In the year to 2026-10-28, 1 member of Congress disclosed buying MEDP and 2 members disclosed selling it; the latest on record is a purchase by David J. Taylor dated 2026-05-15. Insiders filed 8 Form 144 notices of intent to sell in the 90 days to 2026-10-28, covering $26.7M of stock. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
